This is the authors' abstract. We don't add key points for this paper.
This spring I attendedahastily rescheduled wedding. The groom’s father had metastatic colon cancer and he was not expected to live long enough to participate in the wedding on the originally scheduled date. The father wore white gloves because his hand desquamation was so intense that he was unable to touch others; he hugged his son with a stiff and awkward grip using only his forearms because his neuropathy was so painful. My friend had taken a targeted agent for an unusual genetic mutation. The drug was untested for the colon cancer that was invading his lung and liver. As a patient, he was well aware of the risks of his off-evidence treatment and he accepted them without complaint. His suffering, however, is being wasted. My friend was not in a clinical trial. His severe toxicities and his failure to respond will not inform the other patients who may someday confront his choices; his attending physician is the only person who can learn from the experience. The experience of all patients needs to be used for learning. Personalized medicine—tailoring specific therapies to individual patients based on their genetic mutations—has immense potential, and its potential is increased exponentially if we learn quickly from the successes and failures of the early experiments. During this time of learning, medicine is facing impending resource constraints: if current trends continue, US households will be paying more than their average annual income for health care by about 2029. The vignette shows how easy it is to squander the precious time, resources, and knowledge required to understand and use personalized medicine effectively. This editorial proposes the key strategies we need to assess and improve the quality of that care. Precision medicine begins with genetic testing. Sequencing costs have been dropping precipitously, and conventional wisdom supports genome sequencing for about $1,000 soon. These rapid advances in technology have exceeded our knowledge about using them. Three elements are essential for the proper use of gene sequencing: (1) analytic validity standards, (2) clinical validity, and (3) clinical utility studies. Analytic validity ensures that each individual test is consistently producing the results it is intended to produce. There are no consensus standards for analytic validity in gene sequencing. Oncologists experienced a similar problem with the early testing for the human epidermal growth factor receptor 2 (HER2) gene; the analytic validity was insufficient, and inappropriate therapies were prescribed on the basis of an incorrect laboratory test. Clinical validity is an equally necessary validation. Is the mutation being identified truly significant for the disease? It is tempting to label associations as causative or diagnostic rather than as hypothesis generating. The most important factor is the clinical utility—Does the test contribute to clinical decision making? The answer for theHER2 gene in breast cancer
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lee N. Newcomer (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: